The articles in this supplement are based on presentations given at a PharmaMar-sponsored satellite symposium held at the British Gynaecological Cancer Society annual scientifi c meeting, in July 2014 in London. The articles comprise mainly reviews of published data. They include a review of the recent stratifi cation of the recurrent ovarian cancer population (ROC) into different, identifi able subgroups based on platinum-free interval (PFI). This stratifi cation will help guide treatment sequencing management strategies for these different patient groups. The articles also include a discussion of PFI extension strategies through intercalation of a non-platinum combination, such as trabectedin plus pegylated liposomal doxorubicin (PLD), between platinum therapies, and the survival advantage this brings. Clinical data from the pivotal OVA-301 trial of the non-platinum combination trabectedin + PLD is presented. The last article presents a case history of a UK patient where this sequencing approach has been successfully undertaken.
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